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Modulation of apoptosis by
ischemic preconditioning:
an emerging role for miR-21
Tarek M. El-Achkar1
Ischemic preconditioning (IPC) is a powerful phenomenon whereby an
episode of ischemic injury protects the kidney from subsequent injury.
Xu et al. provide new insights into the protective effects of delayed IPC
and its inhibition of apoptosis by implicating a modulatory role for the
microRNA miR-21. This study adds another layer to our understanding
of IPC, but also hints at the complexity of the system triggered by this
process.
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Acute kidney injury caused by ischemia is
a major cause of mortality and morbidity
in hospitalized patients. Interventions to
reduce the incidence or severity of AKI
could potentially have a significant im-
pact on patient care. Guided by old
observations, it has been appreciated over
the past few decades that an episode of
ischemic kidney injury may confer
protection from subsequent injury, a
phenomenon known as ischemic pre-
conditioning (IPC).1 While the protective
effects of IPC may occur as early as
15 min after the initial ischemic event,2
they can also be delayed, persisting as late
as 12 weeks in some experimental condi-
tions.3 For various reasons, it is difficult
to estimate the occurrence and impor-
tance of IPC clinically. In theory, IPC
could be a relatively common pheno-
menon. For example, patients who
develop transient AKI during prolonged
hospitalization could be benefiting from
IPC and become immune to subsequent
insults. IPC could also be an important
player in transplantation, in which
ischemia–reperfusion is a starting point
for all transplanted kidneys. In addition,
because of its protective and delayed
nature (that is, minimizing subsequent
deviation from normal), the occurrence
of IPC will always be underestimated.
Nevertheless, and despite its potential
clinical relevance, IPC is still not well
understood. Furthermore, unraveling the
cellular and molecular mechanisms un-
derlying the protective effects of IPC is
extremely important, because it could
allow the development of therapeutic
approaches that modulate these same key
pathways independently of IPC.
Multiple mediators and path-
ways may be important in renal IPC,
summarized in Figure 1. IPC also
promotes a state of peripheral immuno-
suppression and recruitment of anti-
inflammatory lymphocytes (regulatory
T cells) to the kidney through unclear
mechanisms.4,5 Early protection and
delayed protection conferred by IPC
share common signaling pathways,
such as activation of pertussis toxin-
sensitive G protein and protein kinase
C.2,6 However, there may also be
time-dependent differential activations
of separate pathways, which could
explain the various waves of protec-
tion conferred by IPC. For example,
free radical generation and Akt activa-
tion play a role in early but not in
delayed IPC.2 Inducible nitric oxide
and the increased expression of heat-
shock proteins could be important
mediators of late preconditioning.2,3,7
Inhibition of JNK/p38 activation could
also be an important determinant of a
delayed IPC.7 This is relevant because
JNK activation could be part of a pro-
apoptotic signal in AKI.8 Although
these studies have been essential in
constructing the chain of molecular
events triggered by IPC, it is not clear
whether these signaling events establish
a redundancy in the system or whether
a cross-talk exists between these various
pathways.
Xu et al.9 (this issue) add another
dimension to our understanding of
the molecular mechanisms implicated
in delayed IPC. They studied the role
of microRNAs in IPC. MicroRNAs
(miRNAs) are short non-coding RNA
sequences that regulate gene expression
by base-pairing with specific mRNAs
predominantly at their 30-untranslated
region, thereby regulating their stability
and translation.10 Several enzyme
complexes are involved in this process;
for instance, Dicer complex cleaves a
pre-miRNA precursor. Argonaute and
other proteins bind the cleaved miRNA
to form the RNA-induced silencing
complex (RISC). Depending on the
degree of base pair matching with
the corresponding mRNA, RISC can
either lead to its degradation or repress
its translation. The role of miRNAs in
kidney diseases in general and specifi-
cally AKI is not fully clear. Wei et al.
from Zheng Dong’s laboratory showed
that targeted deletion of Dicer from
proximal tubules was associated with
protection from AKI, supporting a
role for miRNA in modulating AKI.11
Several miRNAs appear to be differen-
tially expressed by ischemia.11,12
Among these, miR-21 appears to have
antiapoptotic properties, in part by
targeting the expression of program-
med cell death protein 4 (PDCD4).
In fact, using isolated primary renal
cells in vitro, Godwin et al. recently
showed that miR-21 upregulation by
ischemia was associated with decrea-
sed PDCD4 expression and increased
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bcl-2.12 Knock-down of miR-21 in vitro
was associated with decreased survival
of renal cells, and its overexpression
prevented their basal rate of death.
However, when these cells were sub-
jected to ischemia, miR-21 overexpres-
sion was not sufficient to prevent cell
death.12
In this current work, Xu et al. show
that delayed IPC reduces the suscepti-
bility of the kidney to AKI and tubular
apoptosis.9 They used a common
model of IPC7 in which ischemia–
reperfusion was performed 4 days after
IPC. The authors show that miR-21
expression is increased shortly after IPC
and remains elevated throughout the
reperfusion period. They also report
that other miRNAs, such as miR-320,
miR-214, and let-7e, were not signifi-
cantly increased by IPC. Using locked
nucleic acid oligonucleotide inhibitor,
they show that miR-21 knock-down
in vivo after IPC aggravated AKI and
tubular apoptosis compared with non-
specific oligonucleotide, suggesting a
role for miR-21 in IPC. Interestingly,
miR-21 did not affect the severity of
AKI in the absence of IPC. The
protection conveyed by miR-21 could
be explained partially by its inhibitory
effect on PDCD4. Indeed, PDCD4
expression increased when miR-21 was
knocked down after IPC. Finally, the
authors also show9 that increased levels
of hypoxia-inducible factor-1a (HIF1a)
that occur and persist after IPC could
be the link to the upregulation of
miR-21.
This study is important for various
reasons. First, it provides additional
evidence for the importance of miRNAs
in regulating the response of the kidney
to injury in vivo. In addition, this work
underscores the importance of the
antiapoptotic effects of delayed IPC,
which could also complement the find-
ings by the Bonventre group on inhibi-
tion of JNK/p38 by IPC,7 although
Xu et al. did not find a difference in the
activation of JNK by anti-mir-21
treatment.9 The work by Xu et al. also
identifies a potential pathway that links
IPC to inhibition of apoptosis via a
HIF1a–miR-21–PDCD4 axis (Figure 1).
The role of HIF1a in regulating the
transcription of miR-21 is a novel find-
ing, and supports a general role for
HIF1a as a transcription factor for
various miRNAs.10 Finally, this study
generates excitement from a technical
aspect, whereby locked nucleic acid
oligonucleotides are successfully used
in vivo to knock down mir-21. The use
of this technology to manipulate
the levels of miRNA in vivo could
become quite valuable in the study of
miRNAs.
The study also has limitations.
The degree of injury after ischemia–
reperfusion seen by histology and
functionally through measurement of
serum creatinine appears to be mild
compared with that in similar work
done by others, such as Joo et al.2 The
authors address this by citing variability
due to technical and operator-dependent
factors, which could partially explain the
discrepancy. However, because the seve-
rity of kidney injury could affect differen-
tial pathways,3 it will be important to
verify whether the role of miR-21 is
limited to mild injury, or whether its
modulatory role could also be apprecia-
ted in more severe insults. To their credit,
the authors demonstrated the reproduci-
bility of the findings in their model with
a time course extending up to 5 days
after ischemia–reperfusion.
If kidney injury and apoptosis are
aggravated by miR-21 knock-down
after IPC, does this mean that over-
expression of mir-21 after IPC is
beneficial? The study by Xu et al.9 was
not designed to address this question.
In fact, the findings by Godwin et al.
that renal cells overexpressing miR-21
were not protected after ischemia could
argue against this.12 In addition,
Xu et al. also show that inhibition of
miR-21 is detrimental only after IPC,9
suggesting that other factors induced
by IPC are essential for the actions of
miR-21. Therefore, future investiga-
tions are needed to clarify whether the
role of miR-21 in IPC is permissive,
acting as an on/off switch, or whether
the level of miR-21 achieved after IPC
correlates with its antiapoptotic effects.
In addition, studies will also need to
identify what factors induced by IPC
are essential for the activity of miR-21,
and what is the relationship of miR-21
to the pathways already established
for IPC.
In conclusion, this study by Xu
et al.9 uncovers a novel modulatory
role for miR-21 in IPC, and a potential
link between IPC and inhibition of
apoptosis, involving a HIF–miR-21–
PDCD4 axis. The study also under-
scores the complexity of the system
triggered by IPC, and hints at the mul-
tiple challenges facing the transition
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Figure 1 | Signaling pathways triggered by ischemic preconditioning. A summary of
the potential pathways triggered by ischemic preconditioning (IPC) is presented. Few
signaling cascades are common to early and delayed IPC (intersection between the two
Venn diagrams), whereas other pathways are more differentially associated. The novel
findings by Xu et al. suggest that IPC stabilizes hypoxia-inducible factor-1a (HIF1a), which
in turn increases the transcription of miR-21. The latter inhibits the translation of programmed
cell death protein 4 (PDCD4), thereby having an overall role of inhibiting apoptosis.
Other abbreviations: iNOS, inducible nitric oxide synthase; PKC, protein kinase C;
Treg, regulatory T cell.
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from understanding molecular mecha-
nisms of IPC to therapeutic applica-
tions. A therapeutic approach to AKI
will probably be multifaceted, targeting
multiple pathways at various times. IPC
is a very powerful phenomenon, speci-
fically because it can trigger multiple
layers of (protective) signaling path-
ways. Therefore, understanding the
interactions between various signaling
pathways and the modulatory role of
miRNAs in IPC will no doubt be
essential.
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Strategies to reverse endothelial
dysfunction in diabetic
nephropathy
Shawn S. Badal1,2 and Farhad R. Danesh1,2,3
Endothelial dysfunction underlies the basic pathophysiology of
microvascular complications of diabetes. Endothelial dysfunction is
associated with impaired nitric oxide (NO) availability. Since NO
production is tightly regulated by endothelial nitric oxide synthase
(eNOS), several therapeutic strategies have been investigated and
proposed to improve eNOS bioavailability in the vasculature. The
findings of Cheng et al. suggest that increased availability of eNOS may
be an effective strategy in restoring endothelial function in patients
with diabetic nephropathy.
Kidney International (2012) 82, 1151–1154. doi:10.1038/ki.2012.306
The critical role of endothelial dysfunc-
tion in micro- and macrovascular com-
plications of diabetes has generated
considerable interest in identifying strate-
gies to improve endothelial function in
the diabetic milieu. An interesting study
by Cheng et al.1 confirms the impor-
tance of endothelial nitric oxide synthase
(eNOS) activity in endothelial dysfunc-
tion, and reports that improving eNOS
activity ameliorates progression of dia-
betic nephropathy. This work provides
evidence for a key role of endothelial
dysfunction in the progression of
diabetic nephropathy, and supports a
rationale for pharmacological targeting
of the eNOS pathway as a novel strategy
in the treatment of diabetic kidney
disease.
The endothelium is not only a
monolayer of endothelial cells that lines
the entire vascular system, but also
exerts significant autocrine, paracrine,
and endocrine actions modulating
vasodilation, smooth muscle cell growth
and migration, and inflammatory res-
ponses. Many of these effects are medi-
ated by nitric oxide (NO). NO opposes
the effects of endothelium-derived vaso-
constrictors such as angiotensin II and
endothelin, protects against endothe-
lial-cell damage induced by cytokines
such as tumor necrosis factor, and
provides antithrombogenic effects by
blocking the release of von Willebrand
factor. Indeed, a defect in the pro-
duction or activity of NO promotes
key features of endothelial dysfunc-
tion, such as vasoconstriction, platelet
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